BioAge plans BGE102 data by year-end, QL-DME data in the second half of next year, and an APJ IND filing by year-end, supported by a little over $350 million in cash through 2029.
BIOA · BioAge Labs, Inc. · Documents
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
BioAge expects two BGE102 readouts later this year and in the second half of next year, plans an APJ IND filing by end of this year, and reported cash just north of 350 million with runway through 29.
BioAge dosed first participants in QUELL-CV and QUELL-DME Phase 2 trials in June 2026 and September 2026. At September 30, 2026, it held $352.3 million in cash, cash equivalents, and marketable securities and expects funding through 2029.
BioAge reported a net loss of $33.5 million for the quarter ended September 30, 2026 and approximately $352.3 million in cash, cash equivalents, and marketable securities. QUELL-CV topline data are anticipated in the fourth quarter of 2026, with funding projected through 2029.
BioAge Labs, Inc. dosed the first participant in QUELL-DME, a randomized, controlled Phase 2 trial of once-daily oral BGE-102 in adults with diabetic macular edema. Topline results are expected in the second half of 2027.